Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis

References

• McElhaney JE. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine 2005; 23(Suppl 1):S10-25
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Dutz JP. Better influenza vaccines for older people: what will it take? J Infect Dis 2008; 198:632-4; PMID:18652548; http://dx.doi.org/10.1086/590435
   PubMed Web of Science ®Google Scholar
• Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet (London, England) 2005; 366:1165-74; PMID:16198765; http://dx.doi.org/10.1016/S0140-6736(05)67339-4
   PubMed Web of Science ®Google Scholar
• Arakane R, Annaka R, Takahama A, Ishida K, Yoshiike M, Nakayama T, Takeshita F. Superior immunogenicity profile of the new intradermal influenza vaccine compared to the standard subcutaneous vaccine in subjects 65 years and older: A randomized controlled phase III study. Vaccine 2015; 33:6650-8; PMID:26519549; http://dx.doi.org/10.1016/j.vaccine.2015.10.088
   PubMed Web of Science ®Google Scholar
• DiazGranados CA, Dunning AJ, Jordanov E, Landolfi V, Denis M, Talbot HK. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season. Vaccine 2013; 31:861-6; PMID:23261045; http://dx.doi.org/10.1016/j.vaccine.2012.12.013
   PubMed Web of Science ®Google Scholar
• Frey SE, Reyes MR, Reynales H, Bermal NN, Nicolay U, Narasimhan V, Forleo-Neto E, Arora AK. Comparison of the safety and immunogenicity of an MF59(R)-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine 2014; 32:5027-34; PMID:25045825; http://dx.doi.org/10.1016/j.vaccine.2014.07.013
   PubMed Web of Science ®Google Scholar
• Rumke HC, Bayas JM, de Juanes JR, Caso C, Richardus JH, Campins M, Rombo L, Duval X, Romanenko V, Schwarz TF, et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008; 26:2378-88; PMID:18407382; http://dx.doi.org/10.1016/j.vaccine.2008.02.068
   PubMed Web of Science ®Google Scholar
• Tsang P, Gorse GJ, Strout CB, Sperling M, Greenberg DP, Ozol-Godfrey A, DiazGranados C, Landolfi V. Immunogenicity and safety of Fluzone((R)) intradermal and high-dose influenza vaccines in older adults >/=65 years of age: a randomized, controlled, phase II trial. Vaccine 2014; 32:2507-17; PMID:24120672; http://dx.doi.org/10.1016/j.vaccine.2013.09.074
   PubMed Web of Science ®Google Scholar
• DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, Pollak R, Christoff J, Earl J, Landolfi V, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. New Eng J Med 2014; 371:635-45; PMID:25119609; http://dx.doi.org/10.1056/NEJMoa1315727
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, Ruiz-Palacios GM, van Essen GA, Caplanusi A, Claeys C, et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis 2013; 13:485-96; PMID:23518156; http://dx.doi.org/10.1016/S1473-3099(13)70046-X
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guidance on influenza vaccines. EMA/CHMP/VWP/457259/2014, July 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/07/WC500170300.pdf
   Google Scholar
• Ohmit SE, Petrie JG, Malosh RE, Cowling BJ, Thompson MG, Shay DK, Monto AS. Influenza vaccine effectiveness in the community and the household. Clin Infect Dis 2013; 56:1363-9; PMID:23413420; http://dx.doi.org/10.1093/cid/cit060
   PubMed Web of Science ®Google Scholar
• Ohmit SE, Petrie JG, Malosh RE, Fry AM, Thompson MG, Monto AS. Influenza vaccine effectiveness in households with children during the 2012-2013 season: assessments of prior vaccination and serologic susceptibility. J Infect Dis 2015; 211:1519-28; PMID:25416812; http://dx.doi.org/10.1093/infdis/jiu650
   PubMed Web of Science ®Google Scholar
• Ohmit SE, Thompson MG, Petrie JG, Thaker SN, Jackson ML, Belongia EA, Zimmerman RK, Gaglani M, Lamerato L, Spencer SM, et al. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis 2014; 58:319-27; PMID:24235265; http://dx.doi.org/10.1093/cid/cit736
   PubMed Web of Science ®Google Scholar
• Sullivan SG, Kelly H. Stratified estimates of influenza vaccine effectiveness by prior vaccination: caution required. Clin Infect Dis 2013; 57:474-6; PMID:23619811; http://dx.doi.org/10.1093/cid/cit255
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. Influenza-associated hospitalizations in the United States. JAMA 2004; 292:1333-40; PMID:15367555; http://dx.doi.org/10.1001/jama.292.11.1333
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-86; PMID:12517228; http://dx.doi.org/10.1001/jama.289.2.179
   PubMed Web of Science ®Google Scholar
• Zambon MC, Stockton JD, Clewley JP, Fleming DM. Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Lancet (London, England) 2001; 358:1410-6; PMID:11705487; http://dx.doi.org/10.1016/S0140-6736(01)06528-X
   PubMed Web of Science ®Google Scholar
• Durviaux S, Treanor J, Beran J, Duval X, Esen M, Feldman G, Frey SE, Launay O, Leroux-Roels G, McElhaney JE, et al. Genetic and antigenic typing of seasonal influenza virus breakthrough cases from a 2008-2009 vaccine efficacy trial. Clin Vaccine Immunol 2014; 21:271-9; PMID:24371255; http://dx.doi.org/10.1128/CVI.00544-13
   PubMed Web of Science ®Google Scholar
• Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G, Tsai T, Clemens R, Rappuoli R. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediat Infect Dis J 2011; 30:1081-5; http://dx.doi.org/10.1097/INF.0b013e3182367662
   PubMed Web of Science ®Google Scholar
• Gravenstein S, Drinka P, Duthie EH, Miller BA, Brown CS, Hensley M, Circo R, Langer E, Ershler WB. Efficacy of an influenza hemagglutinin-diphtheria toxoid conjugate vaccine in elderly nursing home subjects during an influenza outbreak. J Am G S 1994; 42:245-51; http://dx.doi.org/10.1111/j.1532-5415.1994.tb01746.x
   Google Scholar
• McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, Ewen C, Kane KP, Bleackley RC. T cell responses are better correlates of vaccine protection in the elderly. J Immunol (Baltimore, Md : 1950) 2006; 176:6333-9; http://dx.doi.org/10.4049/jimmunol.176.10.6333
   PubMed Web of Science ®Google Scholar
• Shahid Z, Kleppinger A, Gentleman B, Falsey AR, McElhaney JE. Clinical and immunologic predictors of influenza illness among vaccinated older adults. Vaccine 2010; 28:6145-51; PMID:20646987; http://dx.doi.org/10.1016/j.vaccine.2010.07.036
   PubMed Web of Science ®Google Scholar
• Hobson D, Curry R, Beare A, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70(4):767-77; PMID:4509641; http://dx.doi.org/10.1017/S0022172400022610
   PubMedGoogle Scholar
• Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol 2010; 10:18; PMID:20210985; http://dx.doi.org/10.1186/1471-2288-10-18
   PubMed Web of Science ®Google Scholar
• Barrett PN, Berezuk G, Fritsch S, Aichinger G, Hart MK, El-Amin W, Kistner O, Ehrlich HJ. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet (London, England) 2011; 377:751-9; PMID:21329971; http://dx.doi.org/10.1016/S0140-6736(10)62228-3
   PubMed Web of Science ®Google Scholar
• Gorse GJ, O'Connor TZ, Newman FK, Mandava MD, Mendelman PM, Wittes J, Peduzzi PN. Immunity to influenza in older adults with chronic obstructive pulmonary disease. J Infect Dis 2004; 190:11-9; PMID:15195238; http://dx.doi.org/10.1086/421121
   PubMed Web of Science ®Google Scholar
• Hehme N, Künzel W, Petschke F, Türk G, Raderecht C, van Hoecke C, Sänger R. Ten years of experience with the trivalent split-influenza vaccine, Fluarix™. Clin Drug Invest 2002; 22:751-69; http://dx.doi.org/10.2165/00044011-200222110-00004
   Web of Science ®Google Scholar
• Zhou X, McElhaney JE. Age-related changes in memory and effector T cells responding to influenza A/H3N2 and pandemic A/H1N1 strains in humans. Vaccine 2011; 29:2169-77; PMID:21353149; http://dx.doi.org/10.1016/j.vaccine.2010.12.029
   PubMed Web of Science ®Google Scholar